GENDER MEDICINE, INFERTILITY AND ERECTILE FUNCTION: Edited by Ryan Flannigan and Ranjith RamasamyEvaluating collagenase Clostridium histolyticum administration protocols in the treatment of Peyronie's diseasePhillips, Drewa; Chan, Justin Y.H.b; Flannigan, RyanaAuthor Information aDepartment of Urologic Sciences bFaculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Correspondence to Ryan Flannigan, Vancouver General Hospital, 6th Floor Diamond Healthcare Centre, 2775 Laurel Street, Vancouver, BC, Canada V5Z 1M9. Tel: +1 604 875 5003; fax: +1 604 875 5604; e-mail: firstname.lastname@example.org Current Opinion in Urology: May 2020 - Volume 30 - Issue 3 - p 328-333 doi: 10.1097/MOU.0000000000000760 Buy Metrics Abstract Purpose of review Treatment of Peyronie's disease with collagenase Clostridium histolyticum (CCh) has gained world-wide adoption following the phase III clinical trials IMPRESS I and II. However, the optimal treatment parameters remain largely unknown. Many groups have made modifications to CCh treatment in Peyronie's disease in recent years. This review aims to discuss the variations in CCh treatment reported and associated outcomes. Recent findings Variations in CCh treatment protocols include administering higher CCh doses (0.9 mg) less frequently (q1month), use of home penile modeling, use of angulating penile traction devices, and vacuum therapy devices. Authors have reported different injection techniques to include three-point fans and tunneling techniques. Patient selection has expanded to include and evaluate responses among men with some extent of plaque calcification, and ventral curves. Summary Since publication of the IMPRESS trials, several variations of CCh treatment have been reported with similar treatment responses to the original trials. However, future studies are required with prospective, randomized comparative designs to identify the optimal treatment strategies for men with Peyronie's disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.